A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.

Trial Details

NCT ID
NCT05740956
Phase
PHASE1
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • HS-10502
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Males or females aged 18 - 75 years (inclusive).
  • Having at least one target lesion per the RECIST v1.1.
  • For the phase Ia Cohort A: advanced solid tumor carrying HRR gene mutation with failure or intolerance or not available to the currently available …
  • For the phase Ib study:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →